Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) Study
This study is looking at how best to share genetic test results with cancer patients and survivors. It focuses on people with cholangiocarcinoma, multiple myeloma, or early-onset colon or rectal cancer. If you have multiple myeloma, you must be African-American. If you have colon or rectal cancer, you must be African-American and diagnosed at age 65 or younger. The study will offer you choices about what types of genetic results you receive, including information about cancer cells, inherited cancer mutations, and inherited mutations related to other health issues. Researchers want to see how these choices affect your understanding, expectations, and overall satisfaction over about five years.
- Study design
- This interventional study plans to enroll 990 participants. It aims to understand the impact of offering choices in how genetic results are returned.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for an estimated 5 years after completing the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Graham Colditz, M.D., DrPH, MPH · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Participant knowledge of clinical genetic testingThrough completion of follow-up (estimated to be 5 years)
11-item, Likert scale. This scale has 5 points ranging from strongly agree to strongly disagree. 1=Strongly Agree, 2=Agree, 3=Neither Agree nor Disagree, 4=Disagree, 5=Strongly Disagree for items (4, 6-11) are scored such that 'strong disagree' reflects a correct response and 'somewhat disagree' reflects a less confident correct response in the correct direction. Negatively worded items (items 1, 2, 3, and 5) are reverse scored so that 'strongly agree' reflects a correct response and 'somewhat agree' reflect a less confident response in the correct direction. This will be scored by adding up the numbers for each of the 11 items regarding participant knowledge of clinical genetic testing. The total score ranges from 5 to 55. A higher score for the participant represents higher participant knowledge.
- Participant expectations of benefitThrough completion of follow-up (estimated to be 5 years)
Participants will rate their expectation for 6 potential benefits of cancer genomic sequencing on a 4-point scale ranging from extremely unlikely to extremely likely. . 1=Strongly Agree, 2=Agree, 3=Disagree, 4=Strongly Disagree. This will be scored by adding up the numbers for each of the 8 items regarding participant expectations of benefit. The total score ranges from 6 to 24. A higher score for the participant represents higher levels of expectations.
- Participant personal utilityThrough completion of follow-up (estimated to be 5 years)
Participant personal utility will be measured on a 7-point scale ranging from not at all useful to extremely useful. 1=Not at all useful, 2=A little useful, 3=Somewhat useful, 4=Neutral, 5=Useful, 6=Very useful, 7=Extremely useful. This will be scored by adding up the numbers for each of the 14 items regarding participant personal utility. The total score ranges from 14 to 98. A higher score for the participant represents higher personal utility.